Skip to main content
Premium Trial:

Request an Annual Quote

Sense Proteomic Spins out of Procognia

NEW YORK (GenomeWeb News) – Sense Proteomic has spun out of parent firm Procognia to form a stand-alone company that will focus on using a protein array platform aimed at discovering biomarkers for cancer and auto-immune diseases.
 
The Maidenhead, UK-based company has turned to the private equity investment company Apax Partners for financial backing.
 
Financial details of the investment and the spin out were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.